# Ingo K. Mellinghoff

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ingo-k-mellinghoff/

## Facts

| Field | Value |
| --- | --- |
| Citations | 38,706 |
| Field | Glioma Diagnosis and Treatment |
| h-index | 79 |
| i10-index | 168 |
| Last Known Institution | Memorial Sloan Kettering Cancer Center |
| OpenAlex ID | https://openalex.org/A5020324479 |
| ORCID iD | https://orcid.org/0000-0002-4347-8149 |
| Works | 620 |

## Researcher papers

- [Tumor mutational load predicts survival after immunotherapy across multiple cancer types](https://scholariq.org/papers/tumor-mutational-load-predicts-survival-after-immunotherapy-across-multiple/)
- [Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma](https://scholariq.org/papers/neoadjuvant-anti-pd-1-immunotherapy-promotes-a-survival-benefit-with/)
- [Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma](https://scholariq.org/papers/vorasidenib-in-idh1-or-idh2-mutant-low-grade-glioma/)
- [Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma](https://scholariq.org/papers/antitumor-activity-of-rapamycin-in-a-phase-i-trial-for-patients-with-recurrent/)
- [Somatic mutations of the Parkinson's disease–associated gene PARK2 in glioblastoma and other human malignancies](https://scholariq.org/papers/somatic-mutations-of-the-parkinson-s-disease-associated-gene-park2-in/)
- [Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain](https://scholariq.org/papers/epidermal-growth-factor-receptor-activation-in-glioblastoma-through-novel/)
- [Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors](https://scholariq.org/papers/differential-sensitivity-of-glioma-versus-lung-cancer-specific-egfr-mutations-to/)
- [Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial](https://scholariq.org/papers/vorasidenib-a-dual-inhibitor-of-mutant-idh1-2-in-recurrent-or-progressive-glioma/)
- [Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy](https://scholariq.org/papers/bead-based-profiling-of-tyrosine-kinase-phosphorylation-identifies-src-as-a/)
- [Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial](https://scholariq.org/papers/vorasidenib-and-ivosidenib-in-idh1-mutant-low-grade-glioma-a-randomized/)

## Researcher topics

- [Glioma Diagnosis and Treatment](https://scholariq.org/topics/glioma-diagnosis-and-treatment/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Radiomics and Machine Learning in Medical Imaging](https://scholariq.org/topics/radiomics-and-machine-learning-in-medical-imaging/)

## Researcher university

- [Memorial Sloan Kettering Cancer Center](https://scholariq.org/institutions/memorial-sloan-kettering-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.